SF3B4

Across TCGA pan-cancer cohorts, SF3B4 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SF3B4 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher SF3B4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SF3B4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, COAD, and LIHC are the cancer types where SF3B4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.119	0.631	.005	15	view →
COAD	OS	Median	II,III,IV	0.150	0.792	<.001	15	view →
LIHC	OS	Median	All	0.144	0.688	.013	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	All	1.000	0.630	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SF3B4–ACC (OS)

Open the ACC breakdown →